Helga Hagman

Clinical impact of peripherally inserted central catheters vs implanted port catheters in patients with cancer: an open-label, randomised, two-centre trial

Knut Taxbro, Fredrik Hammarskjöld, Bo Thelin et al. · British Journal of Anaesthesia · 2019 · 190 citations · Full text

Medicine, Oncology, Surgery +12

A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT Trial

Anna Johnsson, Helga Hagman, Jan‐Erik Frödin et al. · Annals of Oncology · 2013 · 75 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

Helga Hagman, Jan‐Erik Frödin, Åke Berglund et al. · Annals of Oncology · 2015 · 57 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Cost analysis comparison between peripherally inserted central catheters and implanted chest ports in patients with cancer—A health economic evaluation of the PICCPORT trial

Knut Taxbro, Fredrik Hammarskjöld, David Juhlin et al. · Acta Anaesthesiologica Scandinavica · 2019 · 38 citations

Pharmacy, Oncology, Pharmacoeconomics +17

Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study

Pia Österlund, S. Kinos, Per Pfeiffer et al. · ESMO Open · 2022 · 34 citations · Full text

Medicine, Oncology, Pharmacotherapy +16